Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell TherapyGlobeNewsWire • 12/06/21
Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin's LymphomaGlobeNewsWire • 11/29/21
Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of DirectorsGlobeNewsWire • 11/18/21
Adicet Presents Preclinical Data for ADI-002, a GPC3-Targeted Development Candidate for Solid Tumors, at the SITC Annual MeetingGlobeNewsWire • 11/12/21
Adicet Reports Third Quarter 2021 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/10/21
Adicet Announces Trials in Progress Poster Presentation for ADI-001 at 2021 ASH Annual MeetingGlobeNewsWire • 11/04/21
Adicet to Present Preclinical Data from Allogeneic Gamma Delta T Cell Platform at SITC 36th Annual MeetingGlobeNewsWire • 10/04/21
Twist Bioscience Collaborates with Adicet Bio to Accelerate Discovery of Gamma Delta T Cell Cancer TherapeuticsBusiness Wire • 09/13/21
Adicet Reports Second Quarter 2021 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/12/21
Adicet Reports First Quarter 2021 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/17/21
Week 17 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An EdgeSeeking Alpha • 04/25/21
Adicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 03/11/21
Adicet Bio Announces Initiation of its First-in-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's LymphomaPRNewsWire • 03/10/21